November 6, 2026
Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA
Alfasigma has received expanded approval from the European Commission (EC) for Jyseleca (filgotinib) to treat adult patients living with active axial spondyloarthritis (axSpA).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







